Patent · US Active

Anti-VEGFR2 antibody therapy for hepatocellular carcinoma

US10766961B2 · kind B2 · utility

0Cited by

0References

20Claims

0Family size

Assignee

ImClone LLC · US

Inventors

Paolo B. Abada · Indianapolis, US
Shao-Chun Chang · Carmel, US
Yanzhi Hsu · Berkeley Heights, US
Ling Yang · Lianyungang, CN

Key dates

Filing date	Aug 11, 2015
Grant date	Sep 8, 2020
Priority date	—
Expiry date	Oct 20, 2035

Classification

Technology area (CPC G)Physics
CPC primaryG01N2800/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention provides for a human antibody that binds to human vascular endothelial growth factor receptor 2, preferably ramucirumab, for the treatment of hepatocellular carcinoma (HCC) in patients having levels of alpha-fetoprotein (AFP) of 1.5×ULN (Upper Limit of Normal) or greater, and as a predictive method for the treatment of HCC in patients having AFP levels of 1.5×ULN or greater.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.